Seroatlas · Human Serome Atlas

BTNL2

Butyrophilin-like protein 2

Also known as: BTNL2_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9UIR0
Gene: BTNL2
Canonical length: 482 aa
Protein class: Predicted membrane proteins, Predicted secreted proteins

OverviewNCBI Gene

No narrative summary is available for BTNL2 in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

482 residues, UniProt reviewed canonical sequence.

>Q9UIR0|BTNL2
     1  MVDFPGYNLS GAVASFLFIL LTMKQSEDFR VIGPAHPILA GVGEDALLTC QLLPKRTTMH
    61  VEVRWYRSEP STPVFVHRDG VEVTEMQMEE YRGWVEWIEN GIAKGNVALK IHNIQPSDNG
   121  QYWCHFQDGN YCGETSLLLK VAGLGSAPSI HMEGPGESGV QLVCTARGWF PEPQVYWEDI
   181  RGEKLLAVSE HRIQDKDGLF YAEATLVVRN ASAESVSCLV HNPVLTEEKG SVISLPEKLQ
   241  TELASLKVNG PSQPILVRVG EDIQLTCYLS PKANAQSMEV RWDRSHRYPA VHVYMDGDHV
   301  AGEQMAEYRG RTVLVSDAID EGRLTLQILS ARPSDDGQYR CLFEKDDVYQ EASLDLKVVS
   361  LGSSPLITVE GQEDGEMQPM CSSDGWFPQP HVPWRDMEGK TIPSSSQALT QGSHGLFHVQ
   421  TLLRVTNISA VDVTCSISIP FLGEEKIATF SLSESRMTFL WKTLLVWGLL LAVAVGLPRK
   481  RS

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against BTNL2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.31
Highest tissue expression: 0.8 nTPM

Expression across tissuesHPA

Tissue

lymph node: 0.8 nTPM
small intestine: 0.8 nTPM
gallbladder: 0.6 nTPM
retina: 0.4 nTPM
cerebral cortex: 0.3 nTPM
spleen: 0.3 nTPM

Single-cell type

other brain neurons: 1.1 nCPM
oligodendrocyte progenitor cells: 1 nCPM
bergmann glia: 0.9 nCPM
brain excitatory neurons: 0.9 nCPM
brain inhibitory neurons: 0.5 nCPM
astrocytes: 0.3 nCPM

Immune cell

memory B-cell: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

hypothalamus: 3.6 nTPM
cerebral cortex: 2.7 nTPM
hippocampal formation: 2.3 nTPM
basal ganglia: 2.2 nTPM
midbrain: 2.2 nTPM
pons: 2.1 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about BTNL2.

Disease | AllUniProt

Conditions BTNL2 is implicated in, by any mechanism.

Sarcoidosis 2 (SS2) MIM:612387

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.3
gnomAD pLI: 0
gnomAD missense Z: 1.5

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

signaling receptor binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads BTNL2 as an antibody target. Whether an autoantibody or antibody against BTNL2 could matter depends on whether native BTNL2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

BTNL2 is annotated at the cell surface, where native BTNL2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label BTNL2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...